Pseudobulbar Treatment Market: How Is Dextromethorphan-Quinidine...

a adăugat un sunet Health

2026-07-24 11:05:21 -

Pseudobulbar Treatment Market: How Is Dextromethorphan-Quinidine Fixed-Dose Therapy Becoming the Fastest-Growing Pharmacological Standard?

Dextromethorphan-quinidine fixed-dose combination (Nuedexta, Avanir/Otsuka) — the first FDA-approved therapy specifically indicated for pseudobulbar affect (PBA) in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) patients, modulating glutamatergic and sigma-1 receptor signaling while inhibiting CYP2D6 metabolism — creates the most commercially dynamic market segment,...

0 Commentarii 0 Distribuiri 152 Views 0 previzualizare